The long-term ef®cacy and safety of oral Viagra 1 (sildena®l citrate), a selective phosphodiesterase 5 inhibitor, and the effect of withdrawing treatment were evaluated in men with erectile dysfunction (ED). In 233 men with ED of psychogenic or mixed organicapsychogenic aetiology, 16 weeks of open-label,¯exible-dose sildena®l treatment (10 ± 100 mg) was followed by eight weeks of double-blind, ®xed-dose, randomised withdrawal to placebo or continued treatment with sildena®l. Sildena®l was taken as needed (not more than once daily) approximately 1 h prior to sexual activity. The main outcome measures were a global ef®cacy question, a sexual function questionnaire, an event log of erections, and adverse event recording. In the open-label phase, 200 of 216 patients (93%) reported improved erections with sildena®l; 28 patients (12%) discontinued treatment. In the double-blind phase, the signi®cant improvements in the frequency and duration of erections were maintained in the sildena®l group but returned to pre-treatment values in patients on placebo (P values`0.0001 versus placebo). The most frequent adverse events in the sildena®l group during the double-blind phase were¯ushing (7%), headache (6%), and dyspepsia (5%). Of the 192 patients enrolled in the 1-y extension, 90% completed the study; only two patients (1%) were withdrawn due to lack of ef®cacy. In men with ED of psychogenic or mixed aetiology, oral sildena®l is effective and well-tolerated both at the initiation of therapy and during long-term treatment. For most patients, sildena®l treatment must be continued for improvements in erectile function to be maintained.
Introduction
The inability to achieve or maintain an erection suf®cient for satisfactory sexual performance, referred to as erectile dysfunction (ED) or impotence, is a common condition. 1 Epidemiological studies reporting the prevalence of ED have provided some insights into the scope of the problem. In a survey of 109 British men, aged 16 to over 65 y, 32% reported dif®culty in achieving an erection. 2 The results of the Massachusetts Male Aging Study indicate that 35% of 1290 men aged 40 ± 70 y had moderate or complete ED. 3 Prevalence rates for moderate or complete ED in this population were estimated to be 23% in men aged 40 y and 49% in those 70 y of age. 3 In men aged 80 y, the prevalence of ED of any degree may approach 75%. 4, 5 Various studies have provided information on the number of men with ED among those seeking evaluation for sexual dysfunction. Of 1180 men evaluated at a medical outpatient clinic, 34% had ED. 6 The same prevalence rate ED was found among 212 men surveyed at a family practitioner centre. 7 Moreover ED was the main complaint of more than one third of male partners among couples seeking therapy at sexual problems clinics. 8, 9 At urology clinics, where patients are usually referrals from general practitioners, ED is one of the most prominent conditions in men. 10 Thus, medical practitioners in various specialties are encountering men ED who are seeking treatment.
Penile erection, a haemodynamic event involving a complex interaction of central nervous system and local factors, is dependent on relaxation of the cavernosal arteries and corpus cavernosal smooth muscle. 11 This relaxation leads to an increased blood¯ow into the sinusoidal spaces and cavernosal bodies, resulting in an expansion of the corpora against the tunica albuginea and a reduction in venous out¯ow. Nitric oxide-induced cyclic guanosine monophosphate (cGMP) formation plays a major role in the relaxation of cavernosal smooth muscle and the natural erectile response to sexual stimulation. 12 Viagra 1 (sildena®l citrate) is an orally active, selective inhibitor of cGMP-speci®c phosphodiesterase 5, the predominant phosphodiesterase isozyme of the human corpus cavernosum. 13 By virtue of its ability to inhibit the breakdown of cGMP in penile tissues, sildena®l helps to restore the natural erectile response to sexual stimulation in patients with ED of various aetiologies. 14 This paper reports the results of a multicentre study conducted in the United Kingdom, France, and Norway that evaluated the ef®cacy and safety of oral sildena®l in the long-term treatment of ED as well as the effect of randomised treatment withdrawal.
Patients and methods
Men aged 18 ± 70 y of age with ED of psychogenic or mixed organicapsychogenic aetiology, as assessed by the investigator based predominantly on the medical history and physical examination, and of at least 3 months' duration were eligible for enrolment. Patients also had to have had either at least one Grade 3 or 4 erection (see descriptions below) during the 4 weeks before screening or a positive response to an intracavernosal injection test (papaverine 40 mg or prostaglandin E 1 20 mg). Patients were excluded if they had known vascular, neurological, endocrine, or penile anatomical causes for their ED; a history of major haematological, renal, or hepatic abnormalities; stroke, subarachnoid haemorrhage, bleeding disorder, or peptic ulceration; elevated serum prolactin level; low serum testosterone level; or moderate-to-severe hypertension ( b 170a110 mm Hg) or hypotension (`90a50 mm Hg). Patients regularly receiving concomitant nitrates, anticoagulants, major tranquillisers, oestrogens, or antiandrogens also were excluded. All other therapies for ED were discontinued before the study began. Physical examinations and laboratory safety evaluations were performed at 2 ± 4-week intervals. VIAGRA 1 (sildena®l citrate) and matching placebo were supplied by P®zer Limited. Patients were instructed to take a dose approximately 1 h prior to anticipated sexual activity, but not more than once daily. All participants in the study gave written informed consent. At least 200 men with ED of psychogenic or mixed organicapsychogenic aetiology were needed for enrolment in the 16-week openlabel treatment phase in order to allow at least 100 men to enter the double-blind phase, assuming a maximum rate of discontinuation of 50%.
Study design
The study consisted of four phases: (1) a 2-week, single-blind, placebo run-in phase (in order to exclude from subsequent phases those patients who were satis®ed with improvements in erections during treatment with placebo and those who did not comply with enrolment criteria); (2) a 16-week, open-label,¯exible dose-escalation treatment phase, during which sildena®l was taken as required (not more than once daily) in doses of 10 mg (starting dose), 25 mg, 50 mg, or 100 mg, with the dose adjusted based on ef®cacy and tolerability; (3) an 8-week, double-blind treatment phase, which included a follow-up visit 2 weeks after the end of treatment, in which patients were randomised to receive placebo or to continue sildena®l treatment at their optimal (patient-preferred) dose established in the dose-escalation phase; and (4) after an interval of at least 4 weeks after completing double-blind treatment, patients had the option to enter a 1-y open-label extension phase with a 2-week followup. Patients enrolled in the 1-y, open-label extension started at their optimal dose from the previous phases of the study.
On entry into the study, patients were given an identi®cation code that consisted of their date of birth and initials. For patients who completed the single-blind placebo run-in phase and were eligible for the open-label sildena®l phase, a patient number was allocated according to the order of recruitment. This number was recorded on all blister packs of study medication given to the patient. For the placebo run-in phase, the blister packs contained 14 matching placebo pills and were labelled with the patient identi®cation code and dosing instructions. For the 16-week open sildena®l phase, each centre was supplied with 10 mg and 25 mg of sildena®l as blister packs of 14, with labels having a place to enter the patient number, the blister pack identi®cation letter that corresponded to 10 mg or 25 mg), and dosing instructions. For the doubleblind phase, patients were individually randomised. Study medication (sildena®l or matching placebo) was prepared for 300 patients for each dose in a randomised manner using patient numbers 1 ± 300. Blister packs of 14 pills contained 10 mg or 25 mg of sildena®l or matching placebo and stated dosing instructions. The supplies for the double-blind phase were provided to the investigator, together with a sealed copy of the randomisation code, allowing the investigator to break the code for an individual patient in an emergency. Maintenance of the blinding was checked at the end of the study via examination of the seals. The individuals generating the randomisation assignment were geographically and operationally independent from the study investigators who executed the assignment.
Outcome measures
To evaluate ef®cacy, a global ef®cacy question (`Has the treatment you have been taking improved your 
Statistical analyses
The results of the global ef®cacy question were analysed using logistic regression, with main effect terms for treatment and centre and patient age, duration of ED, aetiology of ED, and smoking as covariates. The mean frequency of responses to each question of the patient sexual function questionnaire were calculated. The responses to the two questions assessing the frequency of erections when sexually stimulated and the frequency of erections lasting as long as they would have liked were based on scales of 1 to 5, with a higher score representing a more favourable response; a score of 0 indicated that the question was not applicable. An analysisof-covariance model was ®tted for each question, which included main effect terms for centre and treatment effect, with baseline score, patient age, smoking, and duration and aetiology of ED as covariates. From the diary, the mean number of Grade 3 erections (hard enough for penetration but not completely hard) or Grade 4 erections (completely hard) achieved in sexual situations per week was calculated and an analysis-of-covariance model as described above was used to determine the association between treatment groups. Intention-totreat analyses were performed on all variables and included all men who had a baseline measurement and at least one measurement after starting treatment. All statistical tests were performed at the 5% level and were two-sided. Since the 1-y extension was an open-label noncomparative phase, data were not subjected to formal statistical testing.
Results
The baseline characteristics of the patients entered in the study are shown in Table 1 . The mean duration of ED was at least 4.8 y in all phases of the study. A majority of the patients reported concomitant conditions, which included hypertension (14%), ischaemic heart disease (12%), diabetes mellitus (7%), and depression (5% At the completion of the 16-week, open-label phase, the proportion of patients receiving each dose of sildena®l was 1% (n 3) at 10 mg, 11% (n 23) at 25 mg, 29% (n 60) at 50 mg, and 58% (n 119) at 100 mg. A total of 200 (93%) of 216 patients responding reported that treatment had improved their erections (Figure 1 ). At the end of 8 weeks of double-blind treatment, 79 of 96 patients (82%) receiving sildena®l indicated that treatment had improved their erections versus 27 of 105 patients (26%) receiving placebo (P`0.0001; Figure 1 ). Long-term ef®cacy and safety of oral Viagra E Christiansen et al
The mean response scores to questions of the patient sexual function questionnaire that assessed the frequency of erections when sexually stimulated and the frequency of erections lasting as long as they would have liked increased signi®cantly during the open-label sildena®l phase (4.31 and 3.91, respectively; P values`0.05 versus baseline; Figure 2 ). These improvements in erectile function were maintained in patients randomised to continue sildena®l during the double-blind phase but returned to pre-treatment (baseline) values in those randomised to placebo. The differences in mean scores between the sildena®l-treated patients and the placebo-treated patients for the frequency of erections when sexually stimulated (4.25 and 2.42, respectively) and the frequency of erections lasting long enough (3.80 and 1.95, respectively) at the end of double-blind treatment were signi®cant (P values 0.0001). The mean scores for these two assessments of erectile function also were maintained by patients receiving open-label sildena®l in the 1-y extension (4.03 and 4.14, respectively). Other questions of the sexual function questionnaire demonstrating a signi®cant difference between sildena®l-treated patients and those on placebo during double-blind treatment included those assessing the ®rmness of erections, sexual satisfaction after taking study drug, and satisfaction with sex life (P values`0.0001). In contrast, no difference between the sildena®l and placebo groups was demonstrated for the frequency of sexual desire (P 0.28).
The mean number of Grade 3 or Grade 4 erections (ie suf®cient hardness for sexual intercourse) per week was 1.6 during open-label sildena®l treatment (Figure 3) . At the end of double-blind treatment, the corresponding value was 1.5 for the sildena®l group and 0.6 for the placebo group (P`0.0001). For patients receiving double-blind sildena®l, 84 of 96 (88%) had at least one Grade 3 or 4 erection in the ®nal 4 weeks of treatment compared with 54 of 105 (51%) receiving placebo (P`0.005); 91% of all Long-term ef®cacy and safety of oral Viagra E Christiansen et al erections were Grade 3 or 4 in these patients taking sildena®l. The proportion of erections that were Grade 3 or 4 in these patients on sildena®l was comparable in patients who had used intracavernosal injection therapy prior to the study and in those who had not (92% and 90%, respectively). The most frequently reported adverse events in the different phases of the study were headache, dyspepsia, and¯ushing (Table 2) , which were predominantly mild or moderate in nature. A small number of patients (four of 233 in the 16-week, open-label phase, two of 98 in the double-blind phase, and nine of 192 in the 1-y extension) reported a mild and transient change in colour hue or brightness perception during sildena®l treatment. However, this adverse event did not cause any patient to discontinue treatment.
A total of 205 patients (88%) completed the initial open-label phase of the study. Of the 28 patients (12%) who discontinued treatment during this phase, in 10 patients (4%) the reasons for discontinuation were related to study drug (seven due to lack of ef®cacy and three due to an adverse event). The three treatment-related adverse events resulting in discontinuation of treatment during the openlabel phase were migraine, nasal congestion, and dyspepsiaaconjunctivitisaeye discomfort (occurring in one patient). An additional three patients discontinued due to an adverse event unrelated to treatment. During the double-blind phase, no patient in the placebo group and three patients (3%) in the sildena®l group discontinued treatment. None of these discontinuations was considered to be related to study medication. In the open-label extension, 172 (90%) completed 1 y of sildena®l treatment. Of the 20 patients (10%) who discontinued treatment, the reason was related to the study drug for four patients (two due to lack of ef®cacy and two due to an adverse event). For the two patients discontinuing treatment due to a treatment-related adverse event, one reported drowsiness and headache and the other nasal congestion and pain. Twenty-four serious adverse events were reported during the course of the 18 months of treatment or within 1 month following the end of treatment; one 66-y-old patient who received 10 mg of sildena®l during the open-label phase of the study experienced a myocardial infarction and subsequently died. None of the serious adverse events was considered by the investigator to be related to sildena®l treatment. Laboratory test results from all study phases indicated no evidence of sildena®l-induced abnormalities.
Discussion
ED is a common medical condition, which represents a considerable burden to both patients and their partners. Loss of self-esteem, anxiety with sexual relationships, and depression are often associated with ED. 1, 3 Two decades ago, ED was considered primarily a psychological disorder and patients were treated with testosterone, psychotherapy, or sex therapy; these treatments were not always effective or accepted by the patient. 16 ± 18 It is now known that the majority of patients have an organic component, together with overlying psychogenic factors, contributing to the aetiology of their ED. 1, 19 Pharmacological treatments that improve erectile function are needed, supplemented when necessary with psychosexual therapy, for the successful management of patients with ED. The ultimate goal of therapy is an effective and reliable therapy that has minimal side effects and is convenient to use, such as an orally active agent. 20 Sildena®l, a selective inhibitor of cGMP-speci®c phosphodiesterase 5, has been shown to restore the natural erectile response to sexual stimulation in patients with ED in both a clinic setting 13 and the home setting. 14 The therapeutic response to sildena®l was comparable in patients with ED with an organic, psychogenic, or mixed aetiology. 14 The present results demonstrate that oral sildena®l restores the natural erectile response to sexual stimulation in patients ED of predominantly mixed organicapsychogenic or psychogenic aetiology. The signi®cant improvements in the frequency of erections and the duration of erections reported by these patients during open-label sildena®l treatment were maintained in those patients randomised to receive sildena®l during the subsequent double-blind treatment phase, but returned to pre-treatment levels in those withdrawn from sildena®l treatment (ie receiving placebo). The improvements in erectile function seen in patients receiving sildena®l also were maintained during the 1-y, open-label extension. These results indicate that, for most patients, Long-term ef®cacy and safety of oral Viagra E Christiansen et al continued treatment with sildena®l is needed to maintain these improvements in erectile function. For the 88% of patients receiving sildena®l who had at least one erection of suf®cient hardness for sexual intercourse during the ®nal 4 weeks of double-blind treatment, the proportion of all erections that were suf®ciently hard for sexual intercourse was virtually the same for patients who had previously used intracavernosal injection therapy and for those who had not (92% and 90%, respectively). Recent studies have reported patientinitiated dropout rates for intracavernosal therapy of 38 ± 59%, with the most common reasons for discontinuing injections being an inadequate response, inconvenience or lack of spontaneity, and adverse events, such as penile pain. 21, 22 Long-term treatment with oral sildena®l was well tolerated. The most frequent adverse events werē ushing, headache, and dyspepsia, which were predominantly mild or moderate in nature. No patient experienced priapism during the study. Overall rates of discontinuation from sildena®l treatment were low.
In conclusion, the results of this study demonstrate the immediate and long-term ef®cacy and safety of oral sildena®l in men with ED of mixed organicapsychogenic or psychogenic aetiology. Furthermore, in most patients, treatment with sildena®l must be continued for the improvements in erectile function to be maintained.
